BB Biotech AG

Swiss Stock Exchange BION.SW

BB Biotech AG Operating Cash Flow for the year ending December 31, 2023

BB Biotech AG Operating Cash Flow is NA for the year ending December 31, 2023. Operating cash flow is cash generated from the company’s regular business operations.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Swiss Stock Exchange: BION.SW

BB Biotech AG

CEO	Dr. Daniel Koller Ph.D.
IPO Date	Jan. 4, 2000
Location	Switzerland
Headquarters	Seestrasse 16
Employees	10
Sector	Health Care
Industries Biotechnology Hedge Funds Private Equity

Description

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Key trends

Past 5 years